Full Text Journal Articles in
Journal J Hematol Oncol

Advertisement

Find full text journal articles






Novel therapies are changing treatment paradigms in metastatic prostate cancer.

Eric Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R Harrison, Christopher J Hoimes, Daniel J George, Andrew J Armstrong, Tian Zhang,

Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair genes has added to the treatment armamentarium and improved personalized treatments for ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):144]

Cited: 0 times

View full text PDF listing >>



Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).

Liling Huang, Shiyu Jiang, Yuankai Shi,

Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then block the activation of downstream signaling pathways. Over the past 20 years, multiple robust and well-tolerated TKIs with ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):143]

Cited: 0 times

View full text PDF listing >>



Advertisement

Retraction Note to: MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway.

Chun-Hua Wei, Gang Wu, Qian Cai, Xi-Can Gao, Fan Tong, Rui Zhou, Rui-Guang Zhang, Ji-Hua Dong, Yu Hu, Xiao- Rong Dong,

An amendment to this paper has been published and can be accessed via the original article. ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):142]

Cited: 0 times

View full text PDF listing >>



Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma.

Kecheng Lei, Xiaoxia Gu, Alvaro G Alvarado, Yuhong Du, Shilin Luo, Eun Hee Ahn, Seong Su Kang, Bing Ji, Xia Liu, Hui Mao, Haian Fu, Harley I Kornblum, Lingjing Jin, Hua Li, Keqiang Ye,

BACKGROUND:Glioblastoma (GBM) is a universally lethal tumor with frequently overexpressed or mutated epidermal growth factor receptor (EGFR). NADPH quinone oxidoreductase 1 (NQO1) and glutathione-S-transferase Pi 1 (GSTP1) are commonly upregulated in GBM. NQO1 and GSTP1 decrease the formation of reactive oxygen species (ROS), which mediates the oxidative stress and promotes ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):141]

Cited: 0 times

View full text PDF listing >>



The functions and clinical significance of circRNAs in hematological malignancies.

Xiangxiang Zhou, Linquan Zhan, Kai Huang, Xin Wang,

With covalently closed circular structures, circular RNAs (circRNAs) were once misinterpreted as by-products of mRNA splicing. Being abundant, stable, highly conserved, and tissue-specific, circRNAs are recently identified as a type of regulatory RNAs. CircRNAs bind to certain miRNAs or proteins to participate in gene transcription and translation. Emerging evidence has ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):138]

Cited: 0 times

View full text PDF listing >>



The specific distribution pattern of IKZF1 mutation in acute myeloid leukemia.

Xiang Zhang, Xuewu Zhang, Xia Li, Yunfei Lv, Yanan Zhu, Jinghan Wang, Jie Jin, Wenjuan Yu,

IKZF1 belongs to the IKAROS family of transcription factors, and its deletion/mutation frequently affects acute lymphoblastic leukemia. In acute myeloid leukemia, IKZF1 deletion has been demonstrated recurrent, but whether IKZF1 mutation also exists in AML remained largely unknown. Herein, we analyzed the IKZF1 mutation in AML. In our cohort, the ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):140]

Cited: 0 times

View full text PDF listing >>



Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.

Lindsey T Brinton, Pu Zhang, Katie Williams, Daniel Canfield, Shelley Orwick, Steven Sher, Ronni Wasmuth, Larry Beaver, Casey Cempre, Jordan Skinner, Matthew Cannon, Mukul Govande, Bonnie Harrington, Amy Lehman, John C Byrd, Rosa Lapalombella, James S Blachly,

Acute myeloid leukemia (AML) is a heterogeneous and complex disease, and treatments for this disease have not been curative for the majority of patients. In younger patients, internal tandem duplication of FLT3 (FLT3-ITD) is a common mutation for which two inhibitors (midostaurin and gilteritinib) with varied potency and specificity for ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):139]

Cited: 0 times

View full text PDF listing >>



Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.

Jorge E Cortes, Marcos de Lima, Hervé Dombret, Elihu H Estey, Sergio A Giralt, Pau Montesinos, Christoph Röllig, Adriano Venditti, Eunice S Wang,

Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and children ≥ 1 month old, and relapsed or refractory CD33 + AML in adults and children ≥ 2 years old. GO treatment has been associated with an increased risk of ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):137]

Cited: 0 times

View full text PDF listing >>



Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment.

Julia López de Andrés, Carmen Griñán-Lisón, Gema Jiménez, Juan Antonio Marchal,

Cancer stem cells (CSCs) represent a tumor subpopulation responsible for tumor metastasis and resistance to chemo- and radiotherapy, ultimately leading to tumor relapse. As a consequence, the detection and eradication of this cell subpopulation represent a current challenge in oncology medicine. CSC phenotype is dependent on the tumor microenvironment (TME), ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):136]

Cited: 0 times

View full text PDF listing >>



High-throughput approaches for precision medicine in high-grade serous ovarian cancer.

Meinusha Govindarajan, Christoph Wohlmuth, Matthew Waas, Marcus Q Bernardini, Thomas Kislinger,

High-grade serous carcinoma (HGSC) is the most prevalent and aggressive subtype of ovarian cancer. The large degree of clinical heterogeneity within HGSC has justified deviations from the traditional one-size-fits-all clinical management approach. However, the majority of HGSC patients still relapse with chemo-resistant cancer and eventually succumb to their disease, evidence ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):134]

Cited: 0 times

View full text PDF listing >>



The altered transcriptome of pediatric myelodysplastic syndrome revealed by RNA sequencing.

Lorena Zubovic, Silvano Piazza, Toma Tebaldi, Luca Cozzuto, Giuliana Palazzo, Viktoryia Sidarovich, Veronica De Sanctis, Roberto Bertorelli, Tim Lammens, Mattias Hofmans, Barbara De Moerloose, Julia Ponomarenko, Martina Pigazzi, Riccardo Masetti, Cristina Mecucci, Giuseppe Basso, Paolo Macchi,

Pediatric myelodysplastic syndrome (PMDS) is a very rare and still poorly characterized disorder. In this work, we identified novel potential targets of PMDS by determining genes with aberrant expression, which can be correlated with PMDS pathogenesis. We identified 291 differentially expressed genes (DEGs) in PMDS patients, comprising genes involved in the ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):135]

Cited: 0 times

View full text PDF listing >>



Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.

Musa Yilmaz, Mansour Alfayez, Courtney D DiNardo, Gautam Borthakur, Tapan M Kadia, Marina Y Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P Patel, Elias J Jabbour, Guillermo Garcia-Manero, Naveen Pemmaraju, Sherry A Pierce, Issa Ghayas, Nicholas J Short, Guillermo Montalban-Bravo, Koichi Takahashi, Rita Assi, Ahmad S Alotaibi, Maro Ohanian, Michael Andreeff, Jorge E Cortes, Hagop M Kantarjian, Farhad Ravandi, Naval G Daver,

BACKGROUND:Second-generation FLT3-inhibitors (FLT3i) demonstrated single-agent composite CR rates (CRc) of 45-55% in patients with relapsed/refractory (R/R) FLT3-mutated AML in phase II/III trials. However, > 85% of patients treated were prior FLT3i naïve. The response rates to sequential FLT3i exposure remain poorly defined. METHODS:We retrospectively reviewed patients with FLT3-mutated AML between November ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):132]

Cited: 0 times

View full text PDF listing >>



Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study.

Julio García-Suárez, Javier de la Cruz, Ángel Cedillo, Pilar Llamas, Rafael Duarte, Víctor Jiménez-Yuste, José Ángel Hernández-Rivas, Rodrigo Gil-Manso, Mi Kwon, Pedro Sánchez-Godoy, Pilar Martínez-Barranco, Blanca Colás-Lahuerta, Pilar Herrera, Laurentino Benito-Parra, Adrián Alegre, Alberto Velasco, Arturo Matilla, María Concepción Aláez-Usón, Rafael Martos-Martínez, Carmen Martínez-Chamorro, Keina Susana-Quiroz, Juan Francisco Del Campo, Adolfo de la Fuente, Regina Herráez, Adriana Pascual, Elvira Gómez, Jaime Pérez-Oteyza, Elena Ruiz, Arancha Alonso, José González-Medina, Lucía Núñez Martín-Buitrago, Miguel Canales, Isabel González-Gascón, María Carmen Vicente-Ayuso, Susana Valenciano, María García Roa, Pablo Estival Monteliu, Javier López-Jiménez, Cristián Escolano Escobar, Javier Ortiz-Martín, José Luis Diez-Martin, Joaquín Martinez-Lopez, ,

BACKGROUND:Patients with cancer have been shown to have a higher risk of clinical severity and mortality compared to non-cancer patients with COVID-19. Patients with hematologic malignancies typically are known to have higher levels of immunosuppression and may develop more severe respiratory viral infections than patients with solid tumors. Data on ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):133]

Cited: 0 times

View full text PDF listing >>



Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.

Guido Lancman, John Mascarenhas, Michal Bar-Natan,

SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation. Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib. She was ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):131]

Cited: 0 times

View full text PDF listing >>



Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.

Yunzhen Qian, Yitao Gong, Zhiyao Fan, Guopei Luo, Qiuyi Huang, Shengming Deng, He Cheng, Kaizhou Jin, Quanxing Ni, Xianjun Yu, Chen Liu,

Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve as targets in precise therapy. Using next-generation sequencing (NGS), these aberrant alterations can be identified and used to develop strategies that will selectively kill cancerous cells in ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):130]

Cited: 0 times

View full text PDF listing >>



Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals.

Kasper Mønsted Pedersen, Yunus Çolak, Stig Egil Bojesen, Børge Grønne Nordestgaard,

BACKGROUND:Increasing evidence suggests that high-density lipoprotein (HDL) may play a role in cancer development. We tested the hypothesis that low HDL levels are associated with increased risk of cancer. METHODS:Individuals from two population-based cohorts, the Copenhagen General Population Study (2003-2015, N = 107 341), and the Copenhagen City Heart Study ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):129]

Cited: 0 times

View full text PDF listing >>



BCMA-targeted immunotherapy for multiple myeloma.

Bo Yu, Tianbo Jiang, Delong Liu,

B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):125]

Cited: 0 times

View full text PDF listing >>



A single-cell survey of cellular hierarchy in acute myeloid leukemia.

Junqing Wu, Yanyu Xiao, Jie Sun, Huiyu Sun, Haide Chen, Yuanyuan Zhu, Huarui Fu, Chengxuan Yu, Weigao E, Shujing Lai, Lifeng Ma, Jiaqi Li, Lijiang Fei, Mengmeng Jiang, Jingjing Wang, Fang Ye, Renying Wang, Ziming Zhou, Guodong Zhang, Tingyue Zhang, Qiong Ding, Zou Wang, Sheng Hao, Lizhen Liu, Weiyan Zheng, Jingsong He, Weijia Huang, Yungui Wang, Jin Xie, Tiefeng Li, Tao Cheng, Xiaoping Han, He Huang, Guoji Guo,

BACKGROUND:Acute myeloid leukemia (AML) is a fatal hematopoietic malignancy and has a prognosis that varies with its genetic complexity. However, there has been no appropriate integrative analysis on the hierarchy of different AML subtypes. METHODS:Using Microwell-seq, a high-throughput single-cell mRNA sequencing platform, we analyzed the cellular hierarchy of bone marrow samples from 40 ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):128]

Cited: 0 times

View full text PDF listing >>



A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.

Andrea Ghelli Luserna di Rorà, Claudio Cerchione, Giovanni Martinelli, Giorgia Simonetti,

The inhibition of the DNA damage response (DDR) pathway in the treatment of cancer has recently gained interest, and different DDR inhibitors have been developed. Among them, the most promising ones target the WEE1 kinase family, which has a crucial role in cell cycle regulation and DNA damage identification and ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):126]

Cited: 0 times

View full text PDF listing >>



Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.

Runxia Gu, Fang Liu, Dehui Zou, Yingxi Xu, Yang Lu, Bingcheng Liu, Wei Liu, Xiaojuan Chen, Kaiqi Liu, Ye Guo, Xiaoyuan Gong, Rui Lv, Xia Chen, Chunlin Zhou, Mengjun Zhong, Huijun Wang, Hui Wei, Yingchang Mi, Lugui Qiu, Lulu Lv, Min Wang, Ying Wang, Xiaofan Zhu, Jianxiang Wang,

BACKGROUND:Recent evidence suggests that resistance to CD19 chimeric antigen receptor (CAR)-modified T cell therapy may be due to the presence of CD19 isoforms that lose binding to the single-chain variable fragment (scFv) in current use. As such, further investigation of CARs recognize different epitopes of CD19 antigen may be necessary. ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):122]

Cited: 0 times

View full text PDF listing >>



HMGB1 in inflammation and cancer.

Shumin Wang, Yi Zhang,

High mobility group box 1 (HMGB1) is a non-histone chromatin-associated protein widely distributed in eukaryotic cells and is involved in DNA damage repair and genomic stability maintenance. In response to stimulus like bacteria or chemoradiotherapy, HMGB1 can translocate to extracellular context as a danger alarmin, activate the immune response, and ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):116]

Cited: 0 times

View full text PDF listing >>



Modeling tumor development and metastasis using paired organoids derived from patients with colorectal cancer liver metastases.

He Li, Weixing Dai, Xi Xia, Renjie Wang, Jing Zhao, Lingyu Han, Shaobo Mo, Wenqiang Xiang, Lin Du, Guangya Zhu, Jingjing Xie, Jun Yu, Nan Liu, Mingzhu Huang, Jidong Zhu, Guoxiang Cai,

Tumor metastasis accounts for the majority of cancer-related deaths; it is therefore important to develop preclinical models that faithfully recapitulate disease progression. Here, we generated paired organoids derived from primary tumors and matched liver metastases in the same colorectal cancer (CRC) patients. Despite the fact that paired organoids exhibit comparable ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):119]

Cited: 0 times

View full text PDF listing >>



Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.

Win Topatana, Sarun Juengpanich, Shijie Li, Jiasheng Cao, Jiahao Hu, Jiyoung Lee, Kenneth Suliyanto, Diana Ma, Bin Zhang, Mingyu Chen, Xiujun Cai,

Synthetic lethality is a lethal phenomenon in which the occurrence of a single genetic event is tolerable for cell survival, whereas the co-occurrence of multiple genetic events results in cell death. The main obstacle for synthetic lethality lies in the tumor biology heterogeneity and complexity, the inadequate understanding of synthetic ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):118]

Cited: 0 times

View full text PDF listing >>



tRNA-derived RNA fragments in cancer: current status and future perspectives.

Mengqian Yu, Bingjian Lu, Jisong Zhang, Jinwang Ding, Pengyuan Liu, Yan Lu,

Non-coding RNAs (ncRNAs) have been the focus of many studies over the last few decades, and their fundamental roles in human diseases have been well established. Transfer RNAs (tRNAs) are housekeeping ncRNAs that deliver amino acids to ribosomes during protein biosynthesis. tRNA fragments (tRFs) are a novel class of small ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):121]

Cited: 0 times

View full text PDF listing >>



Roles of METTL3 in cancer: mechanisms and therapeutic targeting.

Chengwu Zeng, Wanxu Huang, Yangqiu Li, Hengyou Weng,

N6-methyladenosine (m6A) is the most abundant mRNA modification and is catalyzed by the methyltransferase complex, in which methyltransferase-like 3 (METTL3) is the sole catalytic subunit. Accumulating evidence in recent years reveals that METTL3 plays key roles in a variety of cancer types, either dependent or independent on its m6A RNA ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2020, 13(1):117]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0135 s